Efficacy of Azvudine Plus Dexamethasone in Severe Hospitalized Patients with Omicron Infection: a Prospective Multicenter Study

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Dec 9

PMID 39650837

Authors

Meng-Lan Zhang

Xiao-Ying Wei

Nan Su

Jung-Hong Jiang

Guo-Peng Xu

Da-Xiong Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Azvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19. However, there is no evidence in severe hospitalized COVID-19 patients.

Methods: In this multicenter study, we analyzed 209 severe hospitalized COVID-19 patients in four hospitals. All the clinical data and the 28-day composite outcomes were recorded. All of the patients were categorized into two groups according to drug: the dexamethasone (DXM) group and the azvudine plus dexamethasone (AZV+DXM) group.

Results: There were no differences in sex, age, BMI, and underlying diseases between the two groups. The ratio of the 28-day composite outcome was lower for the AZV+DXM group than that for the DXM group (16.97% . 31.82%, = 0.029). The viral clearance time was shorter in the AZV+DXM group than in the DXM group (7.32 ± 2.57 . 8.55 ± 2.34 days, = 0.017). The PaO/FiO levels on day 5 (258.89 ± 55.22 . 233.12 ± 60.51, = 0.026) and day 10 (289.48 ± 44.09 . 261.52 ± 37.34, = 0.015) were higher in the AZV+DXM group than the DXM group. However, data on the hospitalization duration of the two groups were similar. Cox analysis showed the benefit of AZV+DXM in the subgroups of ≥65 years old, multiple organ dysfunction syndrome (MODS), cerebrovascular disease, C-reactive protein (CRP) ≥70mg/L, and D-dimer ≥1 µg/L.

Conclusion: This study is the first to indicate that treatment with AZV+DXM might benefit severe Omicron-infected patients compared with DXM treatment alone. This finding demonstrates, at least partly, the necessity of antiviral treatment in severe patients.

References

Wei C, Liu Y, Liu Y, Zhang K, Su D, Zhong M . Clinical characteristics and manifestations in older patients with COVID-19. BMC Geriatr. 2020; 20(1):395. PMC: 7542569. DOI: 10.1186/s12877-020-01811-5. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Zhang W, Yu L, Huang J, Zeng D . Prolonged Viral RNA Shedding Duration in COVID-19. Am J Ther. 2020; 29(6):e759-e760. PMC: 7219830. DOI: 10.1097/MJT.0000000000001200. View

Pantazopoulos I, Mavrovounis G, Kyritsis A, Perlepe G, Miziou A, Gourgoulianis K . Early corticosteroid initiation delays viral RNA clearance in respiratory secretions of COVID-19 patients. Adv Respir Med. 2021; 89(6):624-625. DOI: 10.5603/ARM.a2021.0112. View

Ko J, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R . A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. J Intensive Care Med. 2021; 36(6):673-680. DOI: 10.1177/0885066621994057. View

Tomazini B, Maia I, Cavalcanti A, Berwanger O, Rosa R, Veiga V . Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020; 324(13):1307-1316. PMC: 7489411. DOI: 10.1001/jama.2020.17021. View

Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao X . Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. Aging Dis. 2020; 11(5):1069-1081. PMC: 7505267. DOI: 10.14336/AD.2020.0630. View

Dian Y, Meng Y, Sun Y, Deng G, Zeng F . Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023; 87(2):e24-e27. PMC: 10188372. DOI: 10.1016/j.jinf.2023.05.012. View

Zhu K . Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials. Front Pharmacol. 2023; 14:1228548. PMC: 10484631. DOI: 10.3389/fphar.2023.1228548. View

10.

Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W . Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21(1):1063. PMC: 8514812. DOI: 10.1186/s12879-021-06548-z. View

11.

Lin S, Lee C, Huang A, Chiu T, Chang K, Huang T . Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort study. Int J Infect Dis. 2023; 128:257-264. PMC: 9837153. DOI: 10.1016/j.ijid.2023.01.011. View

12.

Yang H, Wang Z, Jiang C, Zhang Y, Xu M, Zhang Y . Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study. J Med Virol. 2023; 95(7):e28947. DOI: 10.1002/jmv.28947. View

13.

Ji J, Zhang J, Shao Z, Xie Q, Zhong L, Liu Z . Glucocorticoid therapy does not delay viral clearance in COVID-19 patients. Crit Care. 2020; 24(1):565. PMC: 7503440. DOI: 10.1186/s13054-020-03287-6. View

14.

Tang X, Feng Y, Ni J, Zhang J, Liu L, Hu K . Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021; 100(2):116-126. PMC: 7900459. DOI: 10.1159/000512063. View

15.

Koeckerling D, Barker J . Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019. J Infect Dis. 2021; 224(6):934-937. DOI: 10.1093/infdis/jiab328. View

16.

Marrone A, Nevola R, Sellitto A, Cozzolino D, Romano C, Cuomo G . Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study. Clin Infect Dis. 2022; 75(1):e403-e409. PMC: 8807307. DOI: 10.1093/cid/ciac014. View

17.

Spagnuolo V, Guffanti M, Galli L, Poli A, Querini P, Ripa M . Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2020; 10(1):21291. PMC: 7718220. DOI: 10.1038/s41598-020-78039-1. View

18.

Granholm A, Munch M, Myatra S, Vijayaraghavan B, Cronhjort M, Wahlin R . Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Med. 2021; 48(1):45-55. PMC: 8579417. DOI: 10.1007/s00134-021-06573-1. View

19.

Bernal E, Garcia-Villalba E, Pons E, Hernandez M, Baguena C, Puche G . Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status. Med Clin (Barc). 2023; 161(4):139-146. PMC: 10073576. DOI: 10.1016/j.medcli.2023.03.025. View

20.

Yu B, Chang J . Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct Target Ther. 2020; 5(1):236. PMC: 7547293. DOI: 10.1038/s41392-020-00351-z. View